Is PTCT stock a Buy, Sell, or Hold?

Based on our analysis, PTCT is currently a HOLD with moderate confidence. 📊 HOLD: PTCT is fairly valued with market pricing in 1.3% annual growth. Fine to hold or accumulate slowly on dips.

What is the fair value of PTCT stock?

Our analysis estimates the fair value range for PTCT to be between $71.03 and $78.19. The current price is $69.82.

What is the analyst price target for PTCT?

The average Wall Street analyst price target for PTCT is $99.29. This implies a potential upside of 40.8% from current levels.

PTCT Stock Analysis: Buy, Sell, or Hold?

PTCT - PTC Therapeutics, Inc.

PHARMACEUTICAL PREPARATIONS

$69.82

-0.70 (-0.99%) ▼

5d: -2.62%

30d: -11.0%

90d: +0.04%

HOLD

MODERATE Confidence

Protect Your PTCT Gains

Analysis Updated: Aug 21, 2026 12:00 AM ET

Earnings: Jul 30, 2026 0d

Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Aug 19, 2026 at $72.50 · last confirmed Aug 20, 2026

Strength: 7.8/10

Get Alerted When PTCT Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 HOLD: PTCT is fairly valued with market pricing in 1.3% annual growth. Fine to hold or accumulate slowly on dips.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 25.0%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$121.71

Based on 14.5% avg growth

INTRINSIC VALUE TODAY

$75.57

7.6% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: PTCT is currently trading at $69.82, which is considered fair relative to its 30-day fair value range of $71.03 to $78.19. The stock's valuation (Forward PE: 28.2) is in line with its historical norms (27.1). At these levels, the market is pricing in 1.3% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, PTCT is in a uptrend. The price is currently testing key support at $69.79. A bounce from this level would confirm strength, while a break below could signal further downside.

Market Sentiment: The stock scores a mixed 54/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $99.29 (+40.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.

Quick Decision Summary

Current Position FAIR

Historical Trading Range $71.03 - $78.19

Company Quality Score 54/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 73.3%

Protect Your Profits

Holding PTCT? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

NEUTRAL: Price in fair range
NEUTRAL: Mixed technical signals (54/100)
BULLISH: High volume confirmation
BULLISH: Trading 40.8% below Wall St target ($99.29)
NEUTRAL: Market pricing in 1.3% annual earnings growth - fairly valued
NEUTRAL: Bottoming setup forming (54/100) — watch for confirmation

Trading Range Analysis

30-Day Trading Range $71.03 - $78.19

Current vs Trading Range FAIR

Support & Resistance Levels

Support Level $69.79

Resistance Level $75.00

Current Trend Uptrend

Technical data as of Aug 21, 2026

Fundamental Context

Forward P/E (Next Year Est.) 28.21

Wall Street Target $99.29 (+40.8%)

Revenue Growth (YoY) 101.5%

Profit Margin -3.8%

Valuation Premium vs History +1.3% premium

PE vs Historical 28.2 vs 27.1 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): +1.3% (market-implied from PE analysis)

1-Year Target $71.44 (+1%)

2-Year Target $72.37 (+3%)

3-Year Target $73.31 (+4%)

3-Yr Target (if PE normalizes) (PE: 28→27) PE COMPRESSION $70.43 (0%)

Earnings growth offset by PE compression

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 28.2, Growth: 56.6%) $238.00 (+238%)

Base: (SPY PE: 20.1, Growth: 56.6%) $169.34 (+140%)

Bear: (PE: 17.1, Growth: 56.6%) $143.94 (+104%)

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: August 24, 2026 8:40 AM ET
Data refreshes hourly during market hours. Next update: 9:40 AM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is PTCT showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

INSIDERS SELLING

Recent Transactions

Matthew B Klein SELL 2850 shares 2026-04-21

Mark Elliott Boulding SELL 2265 shares 2026-04-06

Lee Scott Golden SELL 829 shares 2026-04-02

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for PTCT.

Create Free Account

Already have an account? Log In

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
BMRN Biomarin Pharmaceutical …	STRONG BUY 29 analysts	$91	42 HOLD
AXSM Axsome Therapeutics Inc	STRONG BUY 19 analysts	$285	66 BUY
ARGX argenx NV ADR	STRONG BUY 22 analysts	$1173	43 HOLD
DNLI Denali Therapeutics Inc	STRONG BUY 19 analysts	$35	50 HOLD
BBIO BridgeBio Pharma Inc	STRONG BUY 19 analysts	$108	52 HOLD

BMRN Biomarin Pharmace…

42 HOLD

AXSM Axsome Therapeuti…

66 BUY

ARGX argenx NV ADR

43 HOLD

DNLI Denali Therapeuti…

50 HOLD

BBIO BridgeBio Pharma …

52 HOLD

Advanced PTCT Option Strategies

Professional options setups generated by AI based on today's PTCT price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for PTCT

PTCT Technical Chart PTCT Price Prediction PTCT Earnings Date PTCT Investment Advisor PTCT Fair Price Analyzer PTCT Options Advisor PTCT Options Chain PTCT Options Analysis PTCT Competitors

Compare PTCT with Peers

PTCT vs RARE
Which one to buy?

PTCT vs AGIO
Which one to buy?

PTCT vs PRTA
Which one to buy?

PTCT vs ENTA
Which one to buy?

PTCT vs PBYI
Which one to buy?

ACDC vs PTCT
Winner: PTCT

ESPR vs PTCT

ERAS vs PTCT
Winner: PTCT

Create New Comparison View All Competitors

Tradestie